Induction Therapy for Advanced-stage Hodgkin Lymphoma
The goal of therapy for patients with advanced-stage Hodgkin lymphoma is to ensure that as many patients as possible are healthy and free of disease decades after completing treatment. To…
Combination Chemoradiotherapy in Early Hodgkin Lymphoma
Combination chemoradiotherapy achieves excellent results for the treatment of localized Hodgkin lymphoma. However, late toxic effects occur, mostly related to the radiotherapy administered after the standard adriamycin, bleomycin, vinblastine, and…
Balancing Risks and Benefits of Therapy for Patients with Favorable-Risk Limited-Stage Hodgkin Lymphoma
Because long-term survival of patients with nonbulky stage IA to IIA Hodgkin lymphoma is dependent on disease control and avoidance of late toxic effects associated with the treatment received, the…
Advancing Antibody Drug Conjugation
The concept of using monoclonal antibodies for delivering drugs to cancer cells has been explored for decades, with early work surrounding nonspecific targets and drugs with low potencies. These studies…
First Hodgkin Cell Line L428 and the CD30 Antigen
Hodgkin’s disease (HD) is a fatal disorder with the unique histologic features of few dysplastic Hodgkin- and Reed-Sternberg (HRS) cells surrounded by an abundance of nonatypical bystander cells in primary…
Brentuximab Vedotin for the Treatment of Patients with Hodgkin Lymphoma
Hodgkin lymphoma (HL) is a relatively rare but highly curable human cancer. Because very few patients relapse and will require subsequent therapy, new drug development for HL has not been…
Modulation of Hepcidin as Therapy for Primary and Secondary Iron Overload Disorders
In this article, the authors discuss new approaches to treating iron overload diseases using hepcidin mimetics or by modulating endogenous hepcidin expression. In particular, the authors discuss lipid nanoparticle encapsulated…
Modulators of Erythropoiesis
Use of new compound such as inhibitors of JAK2 or transforming growth factor β-like molecules might soon revolutionize the treatment of β-thalassemia and related disorders. However, this situation requires careful…
Role of the Hemostatic System on Sickle Cell Disease Pathophysiology and Potential Therapeutics
Recent studies suggest that sickle cell disease (SCD) is a hypercoagulable state contributing to vaso-occlusive events in the microcirculation, resulting in acute and chronic sickle cell–related organ damage. In this…
Inflammatory Mediators of Endothelial Injury in Sickle Cell Disease
Inflammation plays a critical role in the complex pathophysiology of sickle cell disease and drives both the acute and chronic processes leading to vascular injury. Mediators of inflammation, such as…
